A Phase I, non-randomized, open-label, multi-center dose escalation trial of BI 764532 combined with ezabenlimab in patients with small cell lung carcinoma and other neuroendocrine neoplasms expressing DLL3 (NCT05879978)
1. NCT05879978. https://www.clinicaltrials.gov/study/NCT05879978. Accessed April 2024; 2. Mazières J, et al. ESMO 2023. Poster 2028TiP.